Literature DB >> 19452305

The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.

Ingrid M E Desar1, Sasja F Mulder, Alexander B Stillebroer, Dick-Johan van Spronsen, Winette T A van der Graaf, Peter F A Mulders, Carla M L van Herpen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19452305     DOI： 10.1080/02841860902974167

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  27 in total

1.  Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.

Authors:  Benedetto Farsaci; Jack P Higgins; James W Hodge
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

2.  Peering into the aftermath: The inhospitable host?

Authors:  Robert S Kerbel; John M L Ebos
Journal:  Nat Med       Date:  2010-10       Impact factor: 53.440

3.  Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.

Authors:  Terence C Tang; Shan Man; Ping Xu; Giulio Francia; Kae Hashimoto; Urban Emmenegger; Robert S Kerbel
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

Review 4.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Authors:  John M L Ebos; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

Review 5.  Targeted therapies in renal cell cancer: recent developments in imaging.

Authors:  Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven
Journal:  Target Oncol       Date:  2010-07-14       Impact factor: 4.493

Review 6.  Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications.

Authors:  Catherine Frenette; Robert Gish
Journal:  World J Gastroenterol       Date:  2012-02-14       Impact factor: 5.742

7.  Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.

Authors:  Terence C Tang; Shan Man; Christina R Lee; Ping Xu; Robert S Kerbel
Journal:  Neoplasia       Date:  2010-03       Impact factor: 5.715

8.  Molecular imaging of solid tumors: exploiting the potential.

Authors:  Wim J G Oyen; Winette T A van der Graaf
Journal:  Nat Rev Clin Oncol       Date:  2009-10       Impact factor: 66.675

Review 9.  Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

Authors:  John M L Ebos; Christina R Lee; Robert S Kerbel
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

10.  Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer.

Authors:  Kyung-Jin Yun; Woohyeon Kim; Eun Hee Kim; Min-Hee Kim; Dong-Jun Lim; Moo-Il Kang; Bong-Yun Cha
Journal:  Endocrinol Metab (Seoul)       Date:  2014-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.